Arcus Biosciences Inc. has announced initial data from the ARC-20 study, which evaluated the combination of casdatifan and cabozantinib in patients with metastatic kidney cancer. The study reported a confirmed overall response rate of 46% in patients who had at least 12 weeks of follow-up. The combination therapy was well-tolerated and demonstrated a manageable safety profile, with no significant overlapping toxicity between the drugs. These findings support the launch of two new studies: PEAK-1, a Phase 3 trial for immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 trial for first-line ccRCC patients. Arcus Biosciences will discuss these data further in a conference call scheduled for June 2, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.